Drugmakers, PhRMA, BIO Push Back Against FDA Proposal for Nonclinical GLPs

Drug Industry Daily
A A
Several large drugmakers and industry groups commented on FDA’s proposal to require higher quality management standards for nonclinical studies used to support product applications.

To View This Article:

Login

Subscribe To Drug Industry Daily